Skip to main content
. 2010 Sep 9;33(9):553–558. doi: 10.1002/clc.20769

Table 3.

Cardiovascular Events at 7.5 Years Median Follow‐up With and Without Aspirin Treatment at Discharge

Event Incidence (95% CI) Per 1000 Person‐Years Adjusted Hazard Ratioa Adjusted Hazard Ratiob
No Discharge Aspirin Discharge Aspirin HR (95% CI) P Value HR (95%CI) P Value
All‐cause mortality 67 (60, 75) 42 (37, 49) 0.65 (0.55, 0.78) <0.001 0.61 (0.48, 0.78) <0.001
Cardiovascular mortality 36 (31, 42) 19 (15, 24) 0.55 (0.39, 0.78) <0.001 0.46 (0.33, 0.65) <0.001
Myocardial infarction 31 (27, 37) 28 (23, 33) 0.89 (0.70, 1.13) 0.33 0.73 (0.52, 1.02) 0.07
Stroke 16 (13, 20) 16 (12, 20) 1.01 (0.73, 1.40) 0.95 0.80 (0.51, 1.27) 0.35
Death/myocardial infarction/stroke 92 (83, 101) 70 (63, 79) 0.78 (0.67, 0.91) 0.01 0.66 (0.53, 0.81) <0.001

Abbreviations: CI, confidence interval; HR, hazard ratio.

Numbers in table represent no. (95% CI).

a

Discharge aspirin vs. no discharge aspirin, includes adjustment for age and gender.

b

Discharge aspirin vs nondischarge aspirin, includes adjustment for age, gender, diabetes, hypertension, elevated systolic blood pressure, hypercholesterolemia, family history of heart disease, prior aspirin use, prior revascularization, prior myocardial infarction or history of coronary artery disease, ST‐segment depression ≥ 1 mm on electrocardiogram, extracardiac vascular disease, pulmonary edema related to ischemia, and ever smoked.